Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00219024
- Lead Sponsor
- Novartis
- Brief Summary
To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2775
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 8 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in systolic blood pressure after 8 weeks Diastolic blood pressure is < 90 mmHg or a reduction from baseline of > 10 mmHg after 8 weeks Blood pressure < 140/90 mmHg Change from baseline in standing diastolic blood pressure after 8 weeks Change from baseline in standing systolic blood pressure after 8 weeks
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States